

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

- 1. (withdrawn):** A method for treatment of neuropsychiatric disorders which comprises administration of a D-serine transport inhibitor at a dose sufficient to enhance NMDA receptor-mediated neurotransmission in vivo.
- 2. (withdrawn):** The method of claim 1 wherein the disorder is associated with decreased *N*-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission.
- 3. (withdrawn):** The method of claim 1 wherein the disorder is a psychotic disorder.
- 4. (withdrawn):** The method of claim 3 wherein the psychotic disorder is schizophrenia.
- 5. (withdrawn):** The method of claim 1 wherein the disorder is Alzheimer's disease, bipolar illness, depression and anxiety disorders, stroke or epilepsy.
- 6. (withdrawn):** The method of claim 1 wherein the disorder is age associated memory impairment, closed head injury or attention deficit disorder.

7. **(withdrawn):** The method of claim 1 wherein such agent is administered orally.
8. **(withdrawn):** The method of claim 1 wherein a D-serine transport inhibitor is administered parenterally.
9. **(withdrawn):** A method for augmentation of *N-methyl-D*-aspartate receptor-mediated neurotransmission in vivo which comprises administration of a D-serine transport antagonist.
10. **(withdrawn):** The method of claim 1 or 9 wherein the antagonist is an inhibitor of D-serine transport mediated through system ASC.
11. **(withdrawn):** The method of claim 1 or 9 wherein the antagonist is an inhibitor of systems L, N, A or Gly.
12. **(withdrawn):** The method of claim 1 or 9 wherein the antagonist is an inhibitor of alanine-sensitive D-serine transport.
13. **(withdrawn):** The method of claim 1 or 9 where the antagonist is an inhibitor of alanine-insensitive D-serine transport.

- 14. (withdrawn):** The method of claim 1 or 9 wherein the agent is glycyldodecylamide, D-serine dodecylamide (d-ser-da) or D-alanine dodecylamide.
- 15. (withdrawn):** The method of claim 1 or 9 wherein the agent is used in combination with typical or atypical antipsychotics administered orally, parenterally or by depot formulation.
- 16. (withdrawn):** The method of claim 1 or 9 wherein the agent is used in combination with other treatments commonly used in schizophrenia, including but not limited to antidepressants, mood stabilizers, or antianxiety agents.
- 17. (withdrawn):** The method of claim 1 or 9 wherein the agent is used in combination with a glycine transport inhibitor.
- 18. (previously presented):** A composition for treating schizophrenia comprising an effective amount of a selective D-serine transport inhibitor as the active ingredient and a pharmaceutically acceptable carrier.
- 19. (previously presented):** The composition of claim 18, wherein the inhibitor is D-alanine dodecylamide.

**20. (previously presented):** The composition of claim 18 wherein the inhibitor is a serine or alanine compound having effectiveness in inhibiting D-serine transport in vivo.

**21. (previously presented):** The composition of claim 18 wherein the D-serine transport inhibitor is present in an amount sufficient to augment NMDA-mediated neurotransmission and is combined with a typical or atypical antipsychotic agent administerable orally or parenterally.

**22. (currently amended):** The composition of claim 20 wherein the serine or alanine ~~inhibitor~~ compound comprises a hydrophobic group.

**23. (currently amended):** The composition of claim 22 wherein the hydrophobic group is linked to at least one of the C- and N-terminus of the serine or alanine ~~inhibitor~~ compound.

**24. (previously presented):** The composition of claim 22 where the hydrophobic group is selected from the group consisting of a C1-C13 alkyl group, an unsubstituted or substituted phenyl group, a C1-C13 phenylalkyl group, a cyano group, a halogen group and a C1-C13 haloalkyl group.

**25. (withdrawn):** A method of claim 1 wherein a composition of claim 20 is used.

**26. (withdrawn):** A method of claim 9 wherein a composition of claim 20 is used.

**27-44 (canceled).**